Background/Aim: Immune checkpoint inhibitors are mainly used for right-sided, microsatellite instability-high colorectal tumors. In this study, the effects of oral uracil–tegafur plus leucovorin (UFT/LV) chemotherapy on the gene expressions of four immunotherapy targets and the amounts of tumor-infiltrating lymphocytes (TILs) were investigated. Patients and Methods: Data of 260 patients with stage II or stage III colorectal cancer were analyzed. Gene expression and amount of TILs were evaluated using real-time reverse transcription polymerase chain reaction (CRT-PCR) assay and immunohistochemical staining, respectively. Results: Expression of CTLA4 and LAG3 in tumor tissues was significantly increased after UFT/LV chemotherapy, but only in left-sided tumors. The percentage of high-TIL, high-CD3 and high-FoxP3 patients in the UFT/LV group was significantly higher than that in the control group, only in left-sided tumors. Conclusion: The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers.
Poster Session I. Predictive and prognostic factors S29expressional patterns of ANXA1 according to histopathologies were analized by immunohistochemical staining.Results: A total of 106 women were included and the mean age was 46.34±11.5 years old.ANXA1 was strongly expressed in myoepithelial cells compared with epithelial cells in normal breast tissue (n = 73; p = 0.000).A significant loss of ANXA1 staining was observed both in DCIS (n = 7) and IDC (n = 72) compared with normal epithelium (p = 0.000) and fibroadenoma (p = 0.000).There was no significant difference for ANXA1 staining according to TNM stages (p = 0.750), age (p = 0.715), C-erbB2 (p = 0.100), nodal status (p = 0.800), and distant metastasis (p = 0.489), there was but according to hormone receptor status (p = 0.000), p53 (p = 0.054), nuclear grade (p = 0.000), and histologic grade (p = 0.007) in invasive breast cancer.In histologic type, ANXA1 was strongly expressed in medullary carcinoma compared with lobular carcinoma (p = 0.039) and mucinous carcinoma (p = 0.057).In DCIS, the expression of ANXA1 was increased in high Van Nuys score (p = 0.007).There was significant increase of ANXA1 expression after chemotherapy in the patients (n = 13) who treated with neoadjuvant chemotherapy (p = 0.013).However, there was no statistical correlation between ANXA1 expression and lymphocyte infiltration (r = 0.141, p = 0.236).Conclusion: Though further large scaled studies will be required to define the exact mechanism of ANXA1 on the breast cancer, our results showed that ANXA1 expression was in correlation with some prognostic factors and that ANXA1 re-expressed after chemotherapy can imply that ANXA1 may play an important role on cancer development itself and immune response with relation to cancer.
Th2-related immune and inflammatory responses have been implicated in the pathogenesis of atopic dermatitis (AD), but few clinical lines of evidence have been reported regarding how and whether Th2-related responses are associated with other risk factors in the treatment of AD patients. In this study, the associations between the polymorphisms of genes related to the pathophysiology of AD and the efficacy of suplatast tosilate, an oral immunemodulator known to downregulate Th2-related allergic responses, were analyzed in adult patients with chronic AD. Patients were recruited from our previous study, where suplatast tosilate was evaluated for its efficacy when used in combination with topical steroids. The genotypes of 35 single nucleotide polymorphisms (SNPs) of 27 genes related to AD pathogenesis were then determined in 17 responders and 18 non-responders, as defined by the improvement rate in their AD skin scores. While no significant difference in the patient background was observed between responders and non-responders, significant associations were noted between the response to treatment with suplatast tosilate and three SNPs of IL-4 (-590C/T: P=0.04, -33C/T: P=0.04) and IL-12B (1188A/C: P=0.03), but not for the other SNPs. Of note, ethnic differences in the genotype frequencies of IL-4 -590C/T and IL-12B 1188A/C SNPs were found. In conclusion, the present results raise the possibility that AD patients who tend to produce more IL-4 and IL-12 may be susceptible to suplatast tosilate treatment and that ethnic variations should be considered to further understand the role of Th2-related responses.
